Ionis says Phase 3 FUSION trial shows ulefnersen improves function and survival in FUS-ALS - IONS News | RalliesIonis says Phase 3 FUSION trial shows ulefnersen improves function and survival in FUS-ALS
I
IONS• Phase 3 FUSION trial results
- Ionis reported positive topline Phase 3 results for ulefnersen in FUS-ALS, supporting a potential first disease-modifying genetic treatment.
- The study showed better outcomes on a combined measure of function and survival versus placebo, supporting a disease-progression impact.
- Safety profile looked favorable, with most adverse events described as mild to moderate.
- Detailed trial results will be presented at a future medical congress, with a peer-reviewed publication planned in coming months.
- Otsuka plans to seek expedited regulatory submission pathways, starting with discussions with the FDA and other global regulators.
•
